# EDGAR Filing Document

**Accession Number:** 0001533998
**File Stem:** 0001104659-26-042362
**Filing Date:** 2026-4
**Character Count:** 15107
**Document Hash:** df3f7d59e155d15cf4c73658d79bc3df
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-042362.hdr.sgml**: 20260413

**ACCESSION NUMBER**: 0001104659-26-042362

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260410

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260413

**DATE AS OF CHANGE**: 20260413

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** DarioHealth Corp.
- **CENTRAL INDEX KEY:** 0001533998
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 452973162
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37704
- **FILM NUMBER:** 26856526

**BUSINESS ADDRESS:**
- **STREET 1:** 322 W 57TH ST. #33B
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10019
- **BUSINESS PHONE:** 972-4-770-6377

**MAIL ADDRESS:**
- **STREET 1:** 322 W 57TH ST. #33B
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10019

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LabStyle Innovations Corp.
- **DATE OF NAME CHANGE:** 20111101

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of Earliest Event Reported): April 10, 2026

**DARIOHEALTH CORP.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-37704** | **45-2973162** |
| (State or other jurisdiction <br> of incorporation) | (Commission<br> File Number) | (IRS Employer<br> Identification No.) |

---

**322 W 57th St.** **, #33B** 

 **New York, New York 10019**

(Address of Principal Executive Offices)

**972- 4-770-6377** 

(Issuer's telephone number)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:

◻ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

◻ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading <br> Symbol(s)** | **Name of exchange on which <br> registered** |
| Common Stock, par value $0.0001 per share | DRIO | The Nasdaq Capital Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

---

| | |
|:---|:---|
| **Item 5.02** | **Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.** |

---

*Appointment of John R. Palumbo to Board of Directors*

 

On April 10, 2026, on the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors, or the Board, of DarioHealth Corp., or the Company, the Board appointed John R. Palumbo as a member of the Board, effective immediately.

Mr. Palumbo, 75, brings more than 40 years of healthcare operating experience across early-stage ventures and Fortune 100 enterprises, guiding organizations through transformative growth, including supporting two companies through IPOs and leading large-scale operational and commercial transformations. Since August 2023, Mr. Palumbo has served on the Board of Directors, and the audit and compensation committees, of PM Pediatrics Management Group, LLC, a specialized urgent care provider that offers comprehensive, evidence-based medical and mental health services for children and young adults from birth through age 26. Since September 2025, Mr. Palumbo has served on the Board of Directors, and the audit and compensation committees, of Lucid Diagnotics Inc. (NASDAQ: LUCD), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Since May 2025, Mr. Palumbo has served on the Board of Directors of ivWatch, LLC, a medical device company that develops and manufactures the world's only FDA-cleared and CE-marked biosensor technology designed to continuously monitor peripheral IV sites for early detection of infiltration and extravasation events. Since September 2025, Mr. Palumbo has served on the Board of Directors, and the compensation committee, of QLess, a cloud-based software company that provides a mobile queuing and appointment scheduling platform designed to eliminate physical waiting lines by allowing customers to join virtual queues via their phones. Since June 2023, Mr. Palumbo has chaired the advisory board of Brado Ai, an AI-driven conversational engagement platform serving health systems.

Mr. Palumbo received a B.S. in Business Management from Widener University. Mr. Palumbo brings to the Board valuable experience from his career in healthcare serving in senior leadership, private equity, management, advisory and industry operating roles.

As remuneration for his service as a director, Mr. Palumbo will receive the same fees as the Company's other non-executive directors. There is no arrangement or understanding between Mr. Palumbo and any other person pursuant to which he was elected as a director, and except as otherwise described herein, there are no transactions in which Mr. Palumbo has an interest requiring disclosure under Item 404(a) of Regulation S-K.

---

| | |
|:---|:---|
| **Item 8.01** | **Other Events.** |

---

On April 13, 2026, the Company issued a press release announcing the appointment of Mr. Palumbo to its Board. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.** |

---

(d) Exhibits.

<u>Exhibit Number</u>   <u>Description</u> <br> [99.1](tm2611605d1_ex99-1.htm) [Press release dated April 13, 2026.](tm2611605d1_ex99-1.htm) <br> 104 Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Dated: April 13, 2026 | **DARIOHEALTH CORP.** | **DARIOHEALTH CORP.** |
|  | By: | /s/ Chen Franco-Yehuda |
|  | Name: | Chen Franco-Yehuda |
|  | Title: | Chief Financial Officer, Treasurer and Secretary |

---

## Exhibit 99.1

**Exhibit 99.1**

**Dario Appoints Veteran Healthcare Executive John R. Palumbo to Board of <br> Directors to Support Accelerated Commercial Scaling** 

*Mr. Palumbo's deep relationships across health systems, payers and healthcare's senior executive community expected to accelerate Dario's commercial partnerships and position the Company to realize its full strategic value*

 

**NEW YORK, April 13, 2026** – **<u>DarioHealth Corp.</u> (NASDAQ: DRIO)** (the "Company" or "Dario"), a leader in global digital health, today announced the appointment of John R. Palumbo to its Board of Directors. The addition reflects Dario's continued alignment of board composition with its next phase of commercial scaling.

Mr. Palumbo brings more than 40 years of healthcare operating experience across early-stage ventures and Fortune 100 enterprises. His substantial background includes senior leadership roles at AmerisourceBergen Corporation (now Cencora, Inc.), where he led the provider business unit and expanded consulting and technology capabilities into a multibillion-dollar platform serving health systems nationwide, as well as Chief Operating Officer of Allscripts Healthcare Solutions, Inc. (now Veradigm, Inc.) and leadership positions at Shared Medical Systems Corporation (Siemens Aktiengesellschaft).

"John's appointment is highly intentional and strategically valuable," stated Dario's Chief Executive Officer, Erez Raphael. "As we transition from demonstrating the strength of our distribution model to scaling it efficiently through channel partnerships, we are adding leaders to our board who have done exactly that. John brings a rare combination of strategic insight, operational discipline and deep industry relationships that will directly support our growth trajectory. He has been at the center of some of healthcare's most consequential strategic transactions and organizational transformations, and his relationships with senior decision-makers across the payer, provider and health services landscape will be invaluable as we continue to build and scale. We are increasingly confident that the market will come to fully reflect the value we have built – and we are not standing still while that recognition develops."

Mr. Palumbo has guided organizations through transformative growth, including supporting two companies through IPOs and leading large-scale operational and commercial transformations. His experience is particularly relevant to Dario's evolution toward a more capital-efficient, partner-led go-to-market strategy. He brings deep familiarity with the care delivery ecosystem, including the health systems, payers and provider services organizations that are shaping its consolidation – adding a dimension of strategic reach that directly complements Dario's next phase.

In addition to his operating capabilities, Mr. Palumbo is actively engaged in the digital health ecosystem. He currently serves on the boards of PM Pediatrics Management Group, LLC, Lucid Diagnostics Inc., ivWatch, LLC and Qless, Inc., and chairs the advisory board of Brado Cuneo Nollau, LLC, an AI-driven engagement platform serving health systems.

"Dario is at a compelling inflection point," said Mr. Palumbo. "The Company has built a differentiated, integrated solution with strong engagement which is delivering proven economic and clinical outcomes. The opportunity now is to scale that value through the right commercial channels and ensure the Company captures the full strategic opportunity its platform represents. I look forward to working closely with management to help accelerate both our commercial momentum and the value creation this platform deserves."

**About DarioHealth Corp. (NASDAQ: DRIO)**

DarioHealth Corp. (NASDAQ: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.

Dario's user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.

Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com.

**Cautionary Note Regarding Forward-Looking Statements**

This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses its expectation that Mr. Palumbo's experience will directly support its growth trajectory, its belief that adding Mr. Palumbo as a member of the Board will be instrumental in guiding Dario's continued expansion within the payer, provider and health services markets and its expectation that Mr. Palumbo's appointment will accelerate Dario's commercial partnerships and position the Company to realize its full strategic value. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

**DarioHealth Corporate Contacts**

Michael Lipari<br> SVP Corporate Development<br> <u>irteam@dariohealth.com</u><br> +1-201-785-6310

Rob Halpern<br> SVP Marketing

<u>irteam@dariohealth.com</u>